By Barbara Stephenson Posted May 17, 2022 InTouro LCMC Health2022-05-172022-05-17https://cofactorgenomics.com/wp-content/uploads/2016/10/cofactor_logo_dark.pngCofactor Genomicshttps://cofactorgenomics.com/wp-content/uploads/2022/05/touro-logo.jpg200px200px Touro LCMC HealthRecent PostsCofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer PatientsMultidimensional biomarker predicts disease controlCofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain SpinoutCulmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial